Blog Index
The journal that this archive was targeting has been deleted. Please update your configuration.

Quil-A® Literature

Recommended reading about Quil-A® ADJUVANTS:

Leenaars, P.P.A.M.; Hendriksen, C.F.M.; de Leeuw, W.A.; Carat, F.; Delahaut, P.; Fischer, R.; Halder, M.; Hanley, W.C.; Hartinger, J.; Hau, J.; Lindblad, E.B.; Nicklas, W.; Outschoorn, I.M. and Stewart-Tull, D.E.S. (1999).
The Production of Polyclonal Antibodies in Laboratory Animals. The Report and Recommendations of ECVAM/FELASA Workshop 35.
ATLA 27: 70-102.

Williams WV, Kyriako sM, Sharp GC, Braley-Mullen H. (1987).
Effects of the ADJUVANTS SGP and Quil A on the induction of experimental autoimmune thyroiditis in mice.
CellImmunol. 104(2):296-303.

Vanselow BA, Abetz I, Trenfield K. (1985).
A bovine ephemeral fever vaccine incorporating ADJUVANT Quil A: a comparative study using ADJUVANTS Quil A, aluminium hydroxide gel and dextransulphate.
VetRec. 117(2):37-43.

Flebbe LM, Braley-Mullen H. (1986).
Immunopotentiating effects of the ADJUVANTS SGP and Quil A. I. Antibody responses to T-dependent and T-independent antigens.
CellImmunol. 99(1):119-27.

Flebbe LM, Braley-Mullen H. (1986).
Immunopotentiation by SGP and Quil A. II. Identification of responding cell populations.
Cell Immunol. 15;99(1):128-39.

Verheul AF, Versteeg AA, De Reuver MJ, Jansze M, Snippe H. (1989).
Modulation of the immune response to pneumococcal type 14 capsular polysaccharide-protein conjugates by the ADJUVANT Quil A depends
InfectImmun. 57(4):1078-83

Lindblad, E.B. (2007)
Safety Evaluation of Vaccine ADJUVANTS. Chapter 18 in: Vaccine ADJUVANTs and Delivery Systems.
Ed. M. Singh : p 421-444.
John Wiley & Sons Publishers .

Dalsgaard K. (1984).
Assessment of the dose of the immunological ADJUVANT Quil A in mice and guinea pigs, using sheep red blood cells as model antigen.
ZentralblVeterinarmedB. 31(9):718-20.

Dalsgaard K, Jensen MH. (1977)
Saponin ADJUVANTS. VI. The ADJUVANT activity of quil A in trivalent vaccination of cattle and guinea pigs against foot-and-mouth disease.
Acta VetScand. 18(3):367-73.

Dalsgaard K, Jensen MH, SorensenKJ. (1977).
Saponin ADJUVANTS. IV. Evaluation of the ADJUVANT quil A in the vaccination of cattle against foot-and-mouth disease.
Acta VetScand. 18(3):349-60.

Chavali SR, Francis T, Campbell JB. (1987).
An in vitro study of immunomodulatory effects of some saponins.
IntJ Immunopharmacol.9(6):675-83.

Verheul AF, Poolman JT, Snippe H, VerhoefJ. (1991).
The influence of the ADJUVANT Quil A on the epitope specificity of meningococcal lipopolysaccharide anti-carbohydrate antibodies.
Mol Immunol. 28(11):1193-200.

Mowat AM, Donachie AM, Reid G, Jarrett O. (1991).
Immune-stimulating complexes containing Quil A and protein antigen prime class I MHC-restricted T lymphocytes in vivo and are immunogenic by the oral route.
Immunology. 1991 72(3):317-22.

Oosterlaken TA, Brandenburg A, Schielen P, Fransen R, Kraaijeveld CA, Snippe H. (1991).
Efficient induction of Semliki Forest virus and mumps virus neutralizing anti-anti-idiotypicantibodies using Quil A as ADJUVANT.
J ImmunolMethods. 136(2):169-75.

DeVelasco EA, Dekker HA, Antal P, Jalink KP, van Strijp JA, Verheul AF, Verhoe fJ, Snippe H. (1994).
ADJUVANT Quil A improves protection in mice and enhances opsonic capacity of antisera induced by pneumococcal polysaccharide conjugate vaccines.
Vaccine. 12(15):1419-22.

Jackson LA, Opdebeeck JP. (1994)
Quil A and ISCOMs as ADJUVANTS for midgut membrane antigens of Boophilusmicroplus.
ApplParasitol. 35(2):87-98.

Lipford GB, Lehn N, Bauer S, Heeg K, Wagner H. (1994)
The immunodominant peptide from listeriolysinin Quil A liposomes vaccinates CD8+ cytolyticT cells and confers protection to infection.
ImmunolLett. 40(2):101-4.

Lipford GB, Wagner H, Heeg K. (1994)
Vaccination with immunodominant peptides encapsulated in Quil A-containing liposomes induces peptide-specific primary CD8+ cytotoxic T cells.
Vaccine. 12(1):73-80.

White K, Rades T, Kearns P, Toth I, Hook S. (2006)
Immunogenicity of liposomescontaining lipid core peptides and the ADJUVANT Quil A.

Myschik J, Lendemans DG, McBurney WT, Demana PH, Hook S, Rades T.(2006).
On the preparation, microscopic investigation and application of ISCOMs.
Micron. 37(8):724-34.

Pham HL, Shaw PN, Davies NM.(2006).
Preparation of immuno-stimulating complexes (ISCOMs) by ether injection.
IntJ Pharm. 310(1-2):196-202.

Pham HL, Ross BP, McGeary RP, Shaw PN, Hewavitharana AK, Davies NM. (2006).
Saponins from Quillaja saponaria Molina: isolation, characterization and ability to form immunostimulatory complexes (ISCOMs).
CurrDrug Deliv. 3(4):389-97.

Ghochikyan A, Mkrtichyan M, Petrushina I, Movsesyan N, Karapetyan A, Cribbs DH, Agadjanyan MG. (2006).
Prototype Alzheimer’s disease epitope vaccine induced strong Th2-type anti-Abeta antibody response with Alum to Quil A ADJUVANT switch.
Vaccine. 24(13):2275-82.

Moschos SA, Bramwell VW, Somavarapu S, Alpar HO. (2006).
Modulating the ADJUVANTicity of alum by co-administration of muramyldi-peptide (MDP) or Quil-A.
Vaccine. 24(8):1081-6.